Nothing Random About It: The State of Cancer Drug Development at FDA
This article was originally published in RPM Report
Executive Summary
FDA is getting tougher on cancer drug approvals. But stakeholders on all sides-industry, regulators, and patient groups-say that's probably a good thing. Under the leadership of Richard Pazdur, MD, the controversial director of FDA's newly formed Office of Oncology Drug Products, the agency is raising the bar for getting cancer drugs on the market.
You may also be interested in...
The Next Phase In Oncology: FDA’s Pazdur On “Breakthrough” Drug Development
At a small press briefing on personalized medicine, FDA’s top cancer drug reviewer paints a picture of the next phase in cancer drug development.
Translating FDA for Investors: Seattle Genetics Shrugs Off Public Lambasting at ODAC
Actions speak louder than words. That, at least, is how Seattle Genetics urged investors to think about a tongue lashing the company received during an advisory committee review of the cancer agent Adcetris Seattle Genetics may be right on two levels: the practical outcome of the meeting was positive, and the FDA rhetoric may not have been as directly aimed at the sponsor as a warning to all oncology drug developers.
The Year of the Unpartnered Blockbuster? High Profile Applications Raise Big Questions
Several of the highest profile new drug applications pending or expected to be submitted as 2010 begins involve potential blockbuster market opportunities. They also lack Big Pharma partners. Is Big Pharma really that picky? Or are the applications out of step with the regulatory and commercial climate? Either way, intense investor interest will keep FDA in the spotlight.